PURE
PURE Bioscience, Inc.0.0500
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
5.59MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
PURE Bioscience posted Q2 FY2026 revenue of $444,000, up 13.6% y/y from $391,000, driven by higher PURE Hard Surface sales across its end-user network; six-month totals hit $1,152,000, up 21.6% y/y. Gross margins slipped to 53.6% from 58.1% q/q amid product mix shifts, yet operating loss narrowed to $683,000 from $725,000 y/y as SG&A dropped 2.7%. Net loss of $785,000 reflects added interest expense on related-party convertible notes, now totaling $6.1M at 6.3%-7.9% rates maturing 2026-2028. Cash dwindled to $198,000 after $856,000 operating burn, offset by $720,000 fresh notes. One customer took 30% of H1 sales. Going concern doubts loom large.
8-K
Q2 sales up, loss narrows
PURE Bioscience reported Q2 fiscal 2026 net product sales of $443,000, up from $391,000 year-over-year, driven by end-user network growth, while net loss narrowed to $785,000 from $798,000 on lower SG&A. Cash dwindled to $198,000 amid $6.1M notes payable. New PURE Clean launches Q3 post-USDA certification. Sales climb, yet liquidity squeezes.
8-K
Annual meeting votes passed
Pure Bioscience stockholders overwhelmingly elected seven directors—Tom Y. Lee, Ivan Chen, Tom Myers, David M. Rendall, Robert Bartlett, Bernard Blotner, and Darin Zehr—with 96.5% to 98.1% approval at the February 17, 2026 Annual Meeting. They ratified Weinberg & Company as auditors (99.8% yes) and approved executive pay (96.7%). Stockholders boosted authorized common shares from 200M to 250M by 63.9% of outstanding shares. Board continuity locked in.
8-K
Q1 sales up 27%
PURE Bioscience reported fiscal Q1 net product sales of $707,000, up from $555,000 last year, driven by stronger end-user demand. Net loss narrowed to $464,000 from $689,000, while cash climbed to $434,000. Produce and transportation markets gained traction, yet funding hinges on related-party notes.
10-Q
Q1 FY2026 results
PURE Bioscience posted Q1 FY2026 revenue of $708,000, up 27% y/y from $556,000, all from U.S. PURE Hard Surface sales to a top customer at 43%. Gross profit hit $450,000 for a 64% margin, versus 58% last year, while SG&A fell to $743,000 and op loss narrowed to $(379,000) from $(627,000). Net loss of $(464,000) reflected higher interest expense on related-party convertible notes. Cash climbed to $434,000 q/q on $350,000 fresh notes, yet used $250,000 in operations. Debt totals $5.7M at 6.68%-7.88%, maturing 2026-2028. Going concern doubts linger.
IPO
Website
Employees
Sector
Industry
CLX
Clorox Company (The)
99.82-1.90
DQWS
Dswiss Inc
0.04+0.00
HNST
The Honest Company, Inc.
2.86+0.05
PCT
PureCycle Technologies, Inc.
7.84-0.17
PG
Procter & Gamble Company (The)
145.21+0.08
PHH
Park Ha Biological Technology C
0.39-0.00
PLSE
Pulse Biosciences, Inc
14.23+0.10
PTNM
Pitanium Limited
10.39+0.00
PUBC
Purebase Corporation
0.04-0.01
UL
Unilever PLC
64.33-0.71